Legal & General Group PLC Esperion Therapeutics, Inc. Transaction History

Legal & General Group PLC

  • $431 Billion
  • Q3 2025

A detailed history of Legal & General Group PLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 19,464 shares of ESPR stock, worth $56,445. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,464
Previous 19,464 -0.0%
Holding current value
$56,445
Previous $19,000 168.42%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025
BUY
$0.73 - $1.41 $1,403 - $2,711
1,923 Added 10.96%
19,464 $19,000
Q2 2024

Aug 14, 2024
BUY
$1.84 - $3.24 $32,275 - $56,832
17,541 New
17,541 $38,000
Q1 2023

May 15, 2023
BUY
$1.46 - $7.3 $22,657 - $113,288
15,519 Added 65.67%
39,149 $62,000
Q4 2022

Feb 14, 2023
BUY
$5.09 - $8.5 $81,363 - $135,872
15,985 Added 209.09%
23,630 $147,000
Q3 2022

Nov 14, 2022
BUY
$5.45 - $8.13 $4,458 - $6,650
818 Added 11.98%
7,645 $51,000
Q2 2022

Aug 22, 2022
BUY
$4.77 - $6.67 $391 - $546
82 Added 1.22%
6,827 $43,000
Q1 2022

May 16, 2022
BUY
$3.34 - $5.56 $12,050 - $20,060
3,608 Added 115.01%
6,745 $31,000
Q4 2021

Feb 14, 2022
SELL
$4.81 - $11.92 $42,756 - $105,956
-8,889 Reduced 73.91%
3,137 $15,000
Q3 2021

Nov 15, 2021
SELL
$11.34 - $21.37 $81,443 - $153,479
-7,182 Reduced 37.39%
12,026 $145,000
Q2 2021

Aug 12, 2021
SELL
$19.4 - $28.71 $33,581 - $49,697
-1,731 Reduced 8.27%
19,208 $406,000
Q1 2021

May 17, 2021
BUY
$25.12 - $36.89 $47,351 - $69,537
1,885 Added 9.89%
20,939 $588,000
Q4 2020

Feb 12, 2021
SELL
$24.2 - $35.76 $871 - $1,287
-36 Reduced 0.19%
19,054 $495,000
Q3 2020

Nov 13, 2020
SELL
$31.18 - $52.71 $35,545 - $60,089
-1,140 Reduced 5.64%
19,090 $709,000
Q2 2020

Aug 14, 2020
BUY
$30.04 - $51.31 $105,770 - $180,662
3,521 Added 21.07%
20,230 $1.04 Million
Q1 2020

May 14, 2020
SELL
$27.44 - $73.84 $31,309 - $84,251
-1,141 Reduced 6.39%
16,709 $527,000
Q4 2019

Feb 13, 2020
BUY
$35.4 - $59.82 $268,438 - $453,615
7,583 Added 73.86%
17,850 $1.06 Million
Q2 2019

Aug 14, 2019
BUY
$40.1 - $52.33 $19,969 - $26,060
498 Added 5.1%
10,267 $477,000
Q1 2019

May 15, 2019
BUY
$40.11 - $53.57 $14,158 - $18,910
353 Added 3.75%
9,769 $392,000
Q4 2018

Feb 15, 2019
BUY
$36.99 - $59.11 $86,926 - $138,908
2,350 Added 33.26%
9,416 $434,000
Q2 2018

Aug 10, 2018
BUY
$36.2 - $76.4 $11,403 - $24,066
315 Added 4.67%
7,066 $277,000
Q1 2018

May 17, 2018
BUY
$65.94 - $80.76 $155,816 - $190,835
2,363 Added 53.85%
6,751 $488,000
Q4 2017

Feb 13, 2018
BUY
$43.47 - $67.43 $190,746 - $295,882
4,388
4,388 $291,000

Others Institutions Holding ESPR

# of Institutions
214
Shares Held
114M
Call Options Held
643K
Put Options Held
769K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $193M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email